(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 31.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.68%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Ionis Pharmaceuticals's revenue in 2026 is $874,089,000.On average, 28 Wall Street analysts forecast IONS's revenue for 2026 to be $155,729,666,303, with the lowest IONS revenue forecast at $127,519,877,643, and the highest IONS revenue forecast at $172,831,694,880. On average, 28 Wall Street analysts forecast IONS's revenue for 2027 to be $235,815,552,918, with the lowest IONS revenue forecast at $171,169,851,660, and the highest IONS revenue forecast at $363,943,665,180.
In 2028, IONS is forecast to generate $334,861,408,830 in revenue, with the lowest revenue forecast at $219,030,936,396 and the highest revenue forecast at $443,878,324,062.